Tiago Fauth
Stock Analyst at Wells Fargo
(2.18)
# 2,779
Out of 4,920 analysts
145
Total ratings
42.11%
Success rate
-5.7%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $418.91 | -5.71% | 7 | Aug 1, 2025 | |
| WVE Wave Life Sciences | Maintains: Overweight | $24 → $21 | $8.84 | +137.56% | 3 | Jul 31, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $314 → $295 | $304.81 | -3.22% | 6 | Jul 31, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $74 → $78 | $51.11 | +52.61% | 3 | Jul 29, 2025 | |
| INSM Insmed | Maintains: Overweight | $119 → $130 | $111.61 | +16.48% | 6 | Jul 22, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $28.92 | +124.76% | 8 | Jul 10, 2025 | |
| VRNA Verona Pharma | Downgrades: Equal-Weight | $138 → $107 | $105.40 | +1.52% | 7 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $49.21 | +54.44% | 1 | Jun 30, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $23 → $25 | $20.07 | +24.56% | 2 | Jun 12, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $2.70 | +159.26% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $22.45 | +349.89% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.73 | +73.41% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $14.39 | +80.68% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $6.99 | +143.20% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $3.99 | +125.56% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $60.83 | +23.29% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $2.58 | +2,303.10% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $186.59 | -52.30% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $17.44 | +192.43% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $61.93 | +93.77% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $16.51 | -75.77% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.95 | +374.58% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $6.36 | +308.81% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $4.36 | +542.20% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $24.20 | +234.71% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.35 | +2,185.71% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.08 | +1,196.30% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $0.66 | +5,042.94% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $3.40 | +4,311.76% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $37.46 | -22.58% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $2.04 | +538.82% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $2.60 | +400.00% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $0.88 | +127.27% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $674.90 | -49.62% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $300.08 | -13.69% | 1 | Apr 28, 2021 |
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $418.91
Upside: -5.71%
Wave Life Sciences
Jul 31, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $8.84
Upside: +137.56%
United Therapeutics
Jul 31, 2025
Maintains: Equal-Weight
Price Target: $314 → $295
Current: $304.81
Upside: -3.22%
PTC Therapeutics
Jul 29, 2025
Maintains: Overweight
Price Target: $74 → $78
Current: $51.11
Upside: +52.61%
Insmed
Jul 22, 2025
Maintains: Overweight
Price Target: $119 → $130
Current: $111.61
Upside: +16.48%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $28.92
Upside: +124.76%
Verona Pharma
Jul 10, 2025
Downgrades: Equal-Weight
Price Target: $138 → $107
Current: $105.40
Upside: +1.52%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $49.21
Upside: +54.44%
Liquidia
Jun 12, 2025
Maintains: Overweight
Price Target: $23 → $25
Current: $20.07
Upside: +24.56%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $2.70
Upside: +159.26%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $22.45
Upside: +349.89%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.73
Upside: +73.41%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $14.39
Upside: +80.68%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $6.99
Upside: +143.20%
Dec 20, 2024
Initiates: Overweight
Price Target: $9
Current: $3.99
Upside: +125.56%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $60.83
Upside: +23.29%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $2.58
Upside: +2,303.10%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $186.59
Upside: -52.30%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $17.44
Upside: +192.43%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $61.93
Upside: +93.77%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $16.51
Upside: -75.77%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $2.95
Upside: +374.58%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $6.36
Upside: +308.81%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $4.36
Upside: +542.20%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $24.20
Upside: +234.71%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.35
Upside: +2,185.71%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.08
Upside: +1,196.30%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $0.66
Upside: +5,042.94%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $3.40
Upside: +4,311.76%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $37.46
Upside: -22.58%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $2.04
Upside: +538.82%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $2.60
Upside: +400.00%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $0.88
Upside: +127.27%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $674.90
Upside: -49.62%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $300.08
Upside: -13.69%